People with haemorrhagic strokes are more likely to survive if they are treated at a comprehensive stroke centre, according to research published in the Journal of the American Heart Association.
Codman Neuro has launched the Enterprise 2 vascular reconstruction device in Europe. The Enterprise 2 system is the latest generation of the company’s self-expanding stent and delivery system used to treat wide-necked intracranial aneurysms and to help maintain the position of endovascular coils. Codman Neuro is a part of the DePuy Synthes Companies of Johnson & Johnson.
Air pollution, even at moderate levels, has long been recognised as a factor in raising the risk of stroke. A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine, USA, suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults.
Interventional treatments—especially surgery—provide good functional outcomes and a high cure rate for patients with lower-grade arteriovenous malformations (AVMs) of the brain, reports the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Use of either proximal embolic protection devices (P-EPDs) or distal filter embolic protection devices (F-EPDs) during elective carotid artery stenting results in low rates of in-hospital stroke and death, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania, USA.
Silk Road Medical has announced the first US commercial procedure using the Enroute transcarotid neuroprotection system was successfully performed at Mills-Peninsula Medical Center in Burlingame, USA by vascular surgeon John E Rosenman.
With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME (Solitaire with the intention for thrombectomy as primary endovascular treatment) and REVASCAT (Randomized trial of revascularization with Solitaire FR device versus best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight hours of symptom onset), published online first in the New England Journal of Medicine (NEJM) and presented at the European Stroke Organisation conference (17–19 April, Glasgow, UK), add to that of three other trials—MR CLEAN, EXTEND-IA and ESCAPE—that have begun to change the face of ischaemic stroke treatment.
After analysing stroke treatment records, researchers at Rhode Island Hospital in collaboration with researchers from the University of Cincinnati, both USA, learned that women and men have different reasons for being excluded from receiving the common clot-dissolving drug, recombinant tissue plasminogen activator (rt-PA). Importantly, more women had very high blood pressures, which reduced their eligibility to be treated with the highly effective drug. The study was recently published in the American Heart Association’s (AHA) journal, Stroke.
DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients, according to a Yale-led comprehensive genomic analysis of more than 700 brain tumours. One such subtype of the most malignant brain tumour—glioblastoma—possesses thousands of tumour-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival.
Until recently, thrombolytic therapy has been the only proven treatment for acute ischaemic stroke. A recent study in the Netherlands, however, found that interventional thrombectomy improved functional outcomes in patients with emergent cranial large-vessel occlusions, even among patients who had already received tissue plasminogen activator (tPA) for thrombolytic therapy.
The Edge radiosurgery suite, a technology system for rapidly delivering precise, non-invasive surgical procedures in the treatment of cancer, is among the medical innovations that Varian Medical Systems is showcasing at the 27th International Medical Instruments & Equipment Exhibition (26–28 March, Beijing, China).
Numerous individual studies and meta-analyses have demonstrated that people who have migraines with aura are at a higher risk for ischaemic stroke. Citing these and other studies, Loyola University Medical Center neurologists Michael Star, and José Biller, have described the association between stroke and migraine in their chapter in the new text Headache and Migraine Biology and Management.
The VISSIT study has shown that among patients with symptomatic intracranial arterial stenosis, the use of a balloon-expandable stent compared with medical therapy (clopidogrel and aspirin) resulted in an increase of stroke or transient ischaemic attack. The study was published in the 24/31 March issue of the Journal of the American Medical Association (JAMA).
Published ahead-of-print by Spine, the KAST study has demonstrated non-inferiority of the Kiva system (Benvenue Medical) to balloon kyphoplasty for the treatment of vertebral compression fractures.
Neuralstem has announced top line data from the phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints–the maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos